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ABSTRACT
Objective: To determine if monitoring antiphospholipid syndrome (APS) patients on warfarin by factor II activity assay (FIIAA) would decrease 
thrombus risk or if elevating international normalized ratio (INR) goal based on FIIAA would increase bleeding risk.
Methods: A community hospital retrospective chart review was conducted on anticoagulation clinic APS patients (n=49) over 50 months. Patients 
with an APS-associated diagnosis compliant warfarin therapy were included as long as they were at least 18 years of age. Patients were excluded 
if they were monitored in the clinic for <6 months, became pregnant, or developed cancer during the study period. The primary outcome was to 
determine if FIIAA monitoring reduced thrombus risk or increased bleeding risk.
Results: No statistical difference in bleeding event, age, comorbidities, or sex was determined between the FIIAA monitored and non-FIIAA monitored 
group. Thromboembolic events approached statistical significance (p=0.053) in the monitored group. Two of the 3 patients had a subtherapeutic INR 
and one had additional thrombophilias.
Conclusion: Thromboembolic risk was not reduced by FIIAA monitoring in APS patients. INR goal increases based on FIIAA monitoring did not 
increase bleeding risk. A larger study may help determine the most appropriate way to monitor APS patients using warfarin.
Keywords: Antiphospholipid syndrome, Factor II activity assay, Warfarin, Thrombosis, Anticoagulation and bleeding.
INTRODUCTION
Monitoring and management of anticoagulation in antiphospholipid 
patients are challenging, and the most appropriate method of 
anticoagulation monitoring is controversial [1]. The objective of this 
study is to determine if monitoring antiphospholipid syndrome (APS) 
patients on warfarin by factor II activity assay (FIIAA) would decrease 
thrombus risk or if elevating international normalized ratio (INR) goal 
based on FIIAA would increase bleeding risk.
APS is a prothrombotic condition characterized by the presence of 
autoantibodies that target phospholipid-bound proteins [1]. Although 
these antibodies are known to be present in this patient population, it 
is still not completely understood why these antibodies place patients in 
a hypercoagulable state [1]. The development of APS is very rare among 
the general population with 1-5% incidence in young healthy adults. This 
syndrome is more often associated in patients who have been diagnosed 
with systemic lupus erythematosus, anywhere from 12% to 34% of lupus 
patients would test positive for APS. The typical age of onset is around 
30-40 years of age and rarely diagnosed after the age of 60 [2].
It is widely accepted that these patients should be on anticoagulation 
therapy, but what is still debated is how to appropriately monitor these 
patients. The antibodies associated with APS prolong prothrombin 
times. The Coaguchek® INR meter package insert has the following 
limitation of procedure: “The presence of anti-phospholipid 
antibodies (APAs) such as lupus antibodies can potentially lead to 
prolonged clotting times, i.e., elevated INR values. A comparison to an 
APA-insensitive laboratory method is recommended if the presence of 
APAs is known or suspected [3].”
According to the 2012 and 2015 CHEST guidelines, it is recommended 
for patients with APS and previous thromboembolism to be placed on 
vitamin K antagonist therapy with an INR goal range of 2.0-3.0 [4]. 
However, several studies have shown that patients with APS have a 
prolonged prothrombin time due to the antibodies that are present in 
this disease state. The antiphospholipid condition can interfere with 
thromboplastins used in traditional point of care (POC) and venous INR 
monitoring [5-9].
The previous studies have evaluated the correlations of prothrombin to 
INR, FIIAA, and chromogenic factor X (CFX) testing. All studies proved 
that many patients had prolonged prothrombin time, which was 
leading to falsely elevated INR levels in this patient population [5-8,10]. 
The data suggest that alternative monitoring methods such as FIIAA 
and CFX are unaffected by the antibodies that APS patients develop. 
Having more accurate anticoagulation monitoring utilizing the FIIAA 
laboratory test should help prevent recurrent thromboembolism in 
APS patients that may not be protected at the typical INR goal range of 
2-3. However, the debate still exists whether FIIAA or CFX is the most 
reliable method to monitor this patient population. To the author’s 
knowledge, there are no studies comparing the safety and effectiveness 
of monitoring as well as adjusting therapeutic goals of warfarin 




The study was a retrospective chart review conducted on APS patients 
on warfarin therapy seen at all five health system anticoagulation 
clinics. Electronic medical records were reviewed for the diagnosis 
codes of antiphospholipid antibody, anticardiolipin antibody, or lupus 
anticoagulant seen at any of the anticoagulation clinics during the 
study period of April 2010 through July 2015. FIIAA was chosen as 
the phospholipid-independent anticoagulation monitoring test due 
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to the similar monitoring effectiveness and decreased cost compared 
to CFX [4]. The goal or therapeutic FIIAA range was elected to be 
15-25% based on the previous literature recommendations [5-6]. The 
comparative study groups were divided into FIIAA monitored and 
non-FIIAA monitored patients. Patients in the monitored group had 
FIIAA monitored throughout their clinic visits along with POC and 
venous INRs. INR goal ranges were adjusted according to the policy 
in place (Fig. 1). Non-FIIAA monitored group patients were evaluated 
solely by POC INR. Warfarin dose adjustments were based on venous 
INR measurements in the FIIAA monitored group and POC INR in the 
non-FIIAA monitored patients. Adjustments in INR goal ranges were 
based on the FIIAA percentage in the monitored group.
The primary outcome was to evaluate if monitoring FIIAA in APS 
patients would reduce the risk of thrombosis development without 
increasing the risk of a bleeding event.
Thromboembolic events were defined as any clinical evidence of a 
thrombus. Bleeding events were divided into two categories, major, or 
minor based on criteria set by the International Society on Thrombosis 
and Hemostasis [11]. Major bleeding events were defined as: Any event 
that caused fatality, symptomatic bleeding in a critical area or organ, 
hemoglobin decrease by >2 g/dL, or transfusion requiring >2 units of 
whole blood or red blood cells. Minor bleeding included any patient-
reported bleeding and confirmed diagnosis in medical record that did 
not require any additional tests, referrals, or medical visits.
Secondary outcomes included the percentage of patients prescribed an 
INR goal range above 2.0-3.0, percentage of each study group with a 
confirmatory second thrombophilia test at least 12 weeks or more from 
the initial positive thrombophilia test to confirm the APS diagnosis, as 
well as the percentage of patients below and above range during the 
study period.
Inclusion and exclusion criteria
Patients from any health network anticoagulation clinic were included 
if they were >18 years of age and had one of the following diagnoses 
codes: Antiphospholipid antibody (or syndrome), anticardiolipin 
antibody, or lupus anticoagulant. Patients were excluded if they had not 
been followed in the clinic for at least 6 months if they became pregnant 
or were diagnosed with cancer during the review period. Bleeding and 
thromboembolic events were also excluded if they occurred within 
6 weeks of surgery, as they were deemed provoked events. Five patients 
were excluded in the FIIAA monitored group and seven patients in the 
non-FIIAA monitored group. After evaluation of inclusion and exclusion 
criteria, the comparative study groups included 19 patients in the FIIAA 
monitored and 30 patients in the non-FIIAA monitored group.
Data collection and analysis
Data points collected include: Demographics, diagnosis code, if a second 
confirmatory diagnosis thrombophilia test was completed at least 
12 weeks after the first positive thrombophilia test, INR goal ranges, 
FIIAA levels, percentage of INR values above and below goal range, 
comorbidity scores, any thrombosis or bleeding events, and INR (POC 
and/or venous) at the time of thrombosis or bleeding events. The 
Charlson Comorbidity Scores were assessed with a point system based on 
chart diagnosis of the following: Cardiac (previous myocardial infarction, 
stroke, peripheral vascular disease or congestive heart failure), peptic 
ulcer disease, liver disease, renal disease, diabetes, pulmonary disease, 
hemiplegia, cancer, AIDS, and/or rheumatic disease [12].
Statistical analysis
The Minitab® statistical software was utilized to analyze data through 
Northern Kentucky University Burkhardt Consulting Center. A Fischer’s 
exact test was performed for the primary outcomes between the two 
study groups and to detect any difference in male to female ratio in each 
study group. An independent t-test was performed for the differences 
in percent of INRs above or below range as well as age between the 
two study groups. Two-sample t-test was also conducted to determine 
comorbidity score differences among each study group.
RESULTS
After the electronic medical records were reviewed there were a total 
of 61 patients that met inclusion criteria (Fig. 2). Of the 61 patients, 
24 were categorized into the FIIAA monitored group before exclusion 
criteria application. Of the 24 patients, 5 were excluded leaving 19 FIIAA 
monitored study patients: Two for confirmatory testing at 12 weeks 
that was negative, 2 for follow up for <6 months, and 1 with a diagnosis 
of cancer. 37 patients were categorized into the non-FIIAA monitored 
group before exclusion criteria application. Seven patients were excluded 
leaving 30 non-FIIAA monitored patients: Six for follow-up <6 months 
and 1 was a self-diagnosed patient. There were no statistically different 
baseline characteristics among the two groups (Table 1).
Primary outcomes
Three thromboembolic events occurred in the FIIAA monitored group, 
and no thromboembolic events occurred in the non-FIIAA monitored 
group. No statistically significant reduction occurred in thrombosis 
risk between the FIIAA monitored and non-FIIAA monitored patients 
(p=0.053). Two of the three patients had a subtherapeutic INR at 
the time of the thromboembolic event. One of the thromboembolic 
event patients had additional thrombophilias (protein C deficiency 
and methylenetetrahydrofolate reductase heterozygous mutation) 
which would have placed them at higher risk for a thromboembolism 
Fig. 1: Monitoring policy. POC: Point of care, INR: International normalized ratio
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compared to patients who had the singular risk factor for recurrent 
thromboembolism due to APS. On admission for the thromboembolism, 
the multiple thrombophilia patient’s INR was 2.99 (goal 2.8-3.5), and 
the patient was considered to have a warfarin failure. This patient had 
a recurrent thromboembolism after being non-compliant with INR 
monitoring for 4 months. A second patient had limited movement of 
his knee secondary to a knee injury and held his warfarin for 4 days 
without medical advice. He subsequently developed an ultra-sound 
confirmed deep vein thrombosis on the 3rd day of self-holding warfarin 
resulting in an INR of 1.3 (goal 2.5-3.5). A third patient had a pulmonary 
embolism with a subtherapeutic INR of 2.1 (goal 3-4) shortly after a fall.
There was one bleeding event in the non-FIIAA monitored group and 
no bleeding events in the FIIAA monitored patient group, reaching 
no statistically significant difference among the two patient groups 
(p=1.0). One patient in the non-FIIAA monitored group had an episode 
of hematuria with an INR of 3.6. The patient was diagnosed with kidney 
stones during the admission.
Secondary outcomes
A total of 74% of the FIIAA monitored group had a prescribed INR goal 
range above 2.0-3.0 compared to only 16% of the non-FIIAA monitored 
group. In the patients monitored by FIIAA, approximately, 29.16% 
of INRs were below goal range, while 20.4% were above goal range. 
The results were similar in the patients not monitored by FIIAA with 
33.94% of INRs above goal range and 17.74% of INRs below goal range. 
No statistical difference (p=0.347, p=0.315) was detected in the percent 
of INRs above or below goal INR range between study groups (Table 2).
Approximately, 20% of patients in each study group had a confirmatory 
second thrombophilia test at least 12 weeks or more from the 
initial positive thrombophilia test to confirm the APS diagnosis. The 
APS/unknown category was patients with a confirmed APS diagnosis 
by a hematologist or physician from an outside health-care facility 
without laboratory records being able to be confirmed.
DISCUSSION
The best method of anticoagulation monitoring in APS patients is a 
debated topic in the medical literature. INR monitoring instruments 
traditionally used to monitor clotting times in anticoagulated patients 
have limitations of procedure stating patients with APS should 
have a phospholipid-independent measure of anticoagulation [3]. 
Many anticoagulated APS patients are managed by INR monitoring 
alone. The goal of this study is to detect a difference in effective and 
safe monitoring of anticoagulation in APS patients using the FIIAA 
phospholipid-independent test. It is well known that APS patients may 
have a falsely-elevated venous or POC INR [4,5]. For example, a patient 
in the FIIAA monitored study group had an elevated baseline INR of 1.8 
without prior use of an oral anticoagulant.
About three-quarters of the FIIAA monitored had an INR goal range above 
the typical 2-3 range. This was to be expected in the FIIAA monitored 
patients, as INR goal ranges were adjusted according to subtherapeutic 
FIIAA results. The patients in the non-FIIAA monitored group had INR 
goal ranges set by the physician with no recommendations for INR goal 
increases.
The thromboembolic event rate approached statistical significance 
(p=0.053) with 3 patients having a thromboembolic event in the FIIAA 
monitored group. One of the patients presenting with a subtherapeutic 
INR had limited mobility and self-held warfarin doses without medical 
advice. This thromboembolic occurrence would be considered a 
provoked event. With two patients presenting with INR below goal 
range due to dosing or INR monitoring non-compliance, it could be 
argued that only one patient developed a thromboembolism while being 
properly anticoagulated. In addition, one of the thromboembolic events 
was a pulmonary embolism when the patients INR was 2.1 (goal 3-4) 
after being non-compliant with INR monitoring for several months. This 
particular study patient, though non-compliant demonstrates the value Fig. 2: Data collection
Table 2: INRs in range
Secondary outcomes FIIAA monitored group Non‑FIIAA monitored group
% INRs below goal range (p=0.347) 29.16% 33.94%
% INRs above goal range (p=0.315) 20.4% 17.74%
INR: International normalized ratio, FIIAA: Factor II activity assay
Table 1: Baseline characteristics




Age 55.9±16.5 51.2±11.0 0.273
Comorbidity score 2.47±2.74 2.93±1.96 0.530




LA and aCL 1 4
APS/unknown 6 11
FIIAA monitored group sample size=19, Non-FIIAA monitored group sample size=30. Values are expressed as mean±SD. Not significant at **p<0.05 as compared to each 
group using a two-sample t-test. LA: Lupus anticoagulant, aCL: Anti-cardiolipin antibodies, SD: Standard deviation, APS: Antiphospholipid syndrome, FIIAA: Factor II 
activity assay
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of utilizing the FIIAA to truly target the appropriate INR goal range for 
APS patients. Anticoagulation monitoring of this study APS patient by 
INR alone would not have detected a need to increase the INR goal range 
above the standard 2-3 INR goal range. If this particular patient had not 
had their INR goal range increased from 2-3 up to 3-4, they likely would 
have had a recurrent thromboembolism within a presumed effective 
goal if his INR range had remained at the standard 2-3 range.
No statistical difference in bleeding was found between the FIIAA 
monitored or non-FIIAA monitored group. No association for bleeding 
risk was detected for patients with INR goal increases based on 
subtherapeutic FIIAA, but the small sample size may have limited the 
ability to detect a difference in regard to safety and effectiveness.
Only a fifth of the patients in each study group had a confirmatory 
second thrombophilia test at least 12 weeks or more from the initial 
thrombophilia test to confirm the APS diagnosis. False positive tests 
may occur during the acute thromboembolism period and thus a 
second, later test is recommended [7]. The lack of a confirmatory second 
thrombophilia test communicates a need to educate practitioners 
regarding the recommendation for a second thrombophilia test at 
least 12 weeks or more from the first positive thrombophilia test 
to confirm the diagnosis of APS. This study also indicates the lack of 
anticoagulation monitoring practitioners contacting prescribers to 
order a second thrombophilia test to confirm an APS diagnosis.
The previous studies of FIIAA and CFX anticoagulation monitoring have 
shown these tests are unaffected by the antibodies that APS patients 
develop. To the author’s knowledge, there are no studies to compare 
how monitoring and adjusting warfarin therapeutic goals by FIIAA affect 
thromboembolic or bleeding events. This study does confirm previous 
literature regarding the lack of correlation of INR in APS patients as 
evidenced by the amount of FIIAA-monitored patients who had an 
INR goal range adjustment based on FIIAA results. The importance of 
this current study demonstrates the need for larger patient numbers 
and additional studies to detect the effect of the FIIAA monitoring on 
prevention of thromboembolism and effect on bleeding risk.
Limitations
Several known limitations existed throughout this study. The single-
center design and small sample size (n=49) limited the ability to 
detect true thrombosis and bleeding risk between monitoring study 
groups in this patient population. The chance of a thromboembolic 
or bleeding event occurring at another area hospital is also a possible 
limitation due to reliance of patient self-reporting, which could 
have led to underreporting of both thrombosis and bleeding events. 
In addition, >75% of the patients did not meet diagnosis criteria 
for APS, as confirmatory testing at 12 weeks or greater was not 
completed or completed at an unknown outside facility. This lack 
of confirmatory testing limits the applicability to the general APS 
population. The retrospective chart review design also limits the 
amount of information that was able to be collected. If data points 
were missing in the patient chart, there was no method to collect the 
missing information.
CONCLUSIONS
The 2012 and 2015 CHEST guidelines recommend APS patients 
have a goal INR range of 2.0-3.0. Several studies have proven that 
prothrombin time is often prolonged in these patients which lead 
to a lack of protection from venous thromboembolism in patients 
with this more severe thrombophilia. FIIAA, which is unaffected 
by the antibodies that are characteristic in APS, is an alternative 
monitoring option for these patients. This study did not detect a 
significant reduction in thrombosis risk in APS patients whose goal 
INR ranges were adjusted according to FIIAA results, which was 
likely limited by the small patient population and single-center 
design. Although thrombosis risk was not reduced, bleeding events 
were not more likely in the patients with increased INR goal ranges 
secondary to adjustment after subtherapeutic FIIAA. More efficacious 
anticoagulation by customizing an APS patient’s INR goal range with 
FIIAA monitoring may prevent recurrent thromboembolism and needs 
to be further studied in larger, multicentered trials. The prevention 
of recurrent thromboembolism by identifying an APS-customized 
INR range, could potentially reduce morbidity and mortality in APS 
patients, but needs further study.
The current study also demonstrates a need for educating practitioners 
to order a second confirmatory thrombophilia test at least 12 weeks 
apart from the initial positive thrombophilia test.
This study was likely underpowered to detect the safety and 
effectiveness difference between monitoring anticoagulation with or 
without FIIAA in the APS patient. In the future, additional studies with a 
larger amount of patients in multicenter trials will need to be conducted 
to determine the true risk of thrombosis in these patients and how to 
effectively monitor anticoagulation status despite the antibodies that 
are developed in this disease state.
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